about
Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targetsRandomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adultsStreptococcus pneumoniae Otitis Media Pathogenesis and How It Informs Our Understanding of Vaccine Strategies.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine.Development of Streptococcus pneumoniae Vaccines Using Live VectorsIdentification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine.A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection.Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.Conserved surface accessible nucleoside ABC transporter component SP0845 is essential for pneumococcal virulence and confers protection in vivo.Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunityPassive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies.Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children.Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country.Generation and Improvement of Effector Function of a Novel Broadly Reactive and Protective Monoclonal Antibody against Pneumococcal Surface Protein A of Streptococcus pneumoniae.Pneumococcal colonization and invasive disease studied in a porcine modelTLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies.Toll-like receptor (TLR) 2 mediates inflammatory responses to oligomerized RrgA pneumococcal pilus type 1 protein.Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model.Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity.Next generation protein based Streptococcus pneumoniae vaccinesCD4 T cell memory and antibody responses directed against the pneumococcal histidine triad proteins PhtD and PhtE following nasopharyngeal colonization and immunization and their role in protection against pneumococcal colonization in mice.Rationale and prospects for novel pneumococcal vaccines.Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection.A bivalent pneumococcal histidine triad protein D-choline-binding protein A vaccine elicits functional antibodies that passively protect mice from Streptococcus pneumoniae challenge.Age-dependent prevalence of nasopharyngeal carriage of streptococcus pneumoniae before conjugate vaccine introduction: a prediction model based on a meta-analysisDiverse evolutionary patterns of pneumococcal antigens identified by pangenome-wide immunological screening.Otitis-Prone Children Produce Functional Antibodies to Pneumolysin and Pneumococcal Polysaccharides.Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins.The fundamental link between pneumococcal carriage and disease.Genome-based bacterial vaccines: current state and future outlook.Current status and perspectives on protein-based pneumococcal vaccines.Streptococcus pneumoniae infection: a Canadian perspective.Exploitation of physiology and metabolomics to identify pneumococcal vaccine candidates.Age-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic.Immune ageing and susceptibility to Streptococcus pneumoniae.Clinical and Epidemiological Evidence of the Red Queen Hypothesis in Pneumococcal Serotype DynamicsPneumococcal lipoproteins involved in bacterial fitness, virulence, and immune evasion.Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity.
P2860
Q27009118-C0F3B18B-6F7E-42C3-A8CF-D9680DB59B6EQ33601853-DCCB2E1B-88D5-4F3E-ADBE-414AC2E38737Q33733347-0E894D71-AE70-4019-9A7D-CC6EE895126EQ34170021-372171FB-0551-4CC3-B115-4AB972831265Q34298079-2DD515B8-EF69-4845-AA23-5511A4C46503Q34316015-5B227898-4F0D-4F45-ADCC-AEBE7E92577FQ34385066-57B24366-B498-4C44-A2CD-7A7199DAFC90Q34594671-AF381580-69A1-41B6-90AA-9796292D03FFQ34784957-AF831F7F-DF28-4F74-80A0-13695C7E6375Q35092077-A91D6AC7-4472-4DB6-AF95-6074783FA194Q35844906-B6642116-FE22-4A59-A3E1-3052E7DF8648Q35887448-FDDE3A58-9C3F-4A54-A717-7B5A092DA890Q35915846-47B06250-C5C9-4EA4-AA60-ECB9BF9E573BQ36013814-D836ACCE-7621-4AB7-8F0B-858438E1938EQ36015321-EA615835-AE65-4829-A4E4-78514F9A67E0Q36045264-F4F534E0-2577-45A5-8B1A-01B2E8BF5E70Q36552864-47C81301-7B80-4CAC-9331-E39F1809C407Q36555083-15B28DDF-84D2-4866-9842-5002A405232BQ36562085-208145B8-E389-4541-B0A2-53B9A74D4DE9Q36894814-6E885781-E8D0-44A6-90A6-DF6897570C51Q37103959-23153004-CFEF-4E48-802F-F0B6950004A1Q37130191-B0CBED59-00FD-4BBA-AD93-314EDA45A560Q37264678-87B84453-A9ED-4570-A8DA-2944F37A5E07Q37309218-86E3CBA2-72F9-4FC3-89B1-386728BEDE02Q37372514-C091B1DF-D0E7-430D-A55E-2324CD62813FQ37473239-AFFE5BA0-B80C-4388-AEB4-5C22D332EBDDQ37509931-0E9EA6FA-103D-4C3B-A889-13430909E99AQ37598959-884093F2-331A-4E41-8ED9-2909924F205FQ37683735-CC76F1BF-2326-462E-8757-FAEB81CEA481Q37713348-B4136D30-548F-41B9-9B35-F9EE5C919423Q38036689-60F2FA1E-18C9-473B-A094-899C6CDB48F3Q38099207-2DE0A5A3-9B28-492C-A06D-125A073617B4Q38124921-AB539F8A-818A-4330-A30A-8001AE782131Q38131534-F832D246-C622-4650-A5EA-4B2A42D08F10Q38140041-6E290AD9-587B-4FDD-B372-3CAA86FB9151Q38255618-3613118E-299E-4023-B2CB-249B5DC5348EQ38608479-753E72B7-CDA6-4EB5-B46E-DAAFF496A666Q38860505-1E9B4275-C1F7-4870-BE2C-0424B6FA59C7Q38923654-66514A59-79C3-4721-BAB5-324120C8349CQ39164566-44E56983-8563-426D-8CB4-90B7A465480C
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Next generation pneumococcal vaccines
@ast
Next generation pneumococcal vaccines
@en
type
label
Next generation pneumococcal vaccines
@ast
Next generation pneumococcal vaccines
@en
prefLabel
Next generation pneumococcal vaccines
@ast
Next generation pneumococcal vaccines
@en
P2860
P1476
Next generation pneumococcal vaccines
@en
P2093
Kristin L Moffitt
Richard Malley
P2860
P304
P356
10.1016/J.COI.2011.04.002
P577
2011-04-21T00:00:00Z